Moolec Science (MLEC) Interest Coverage Ratio (2023 - 2024)
Moolec Science (MLEC) reported Interest Coverage Ratio of 0.13 for Q4 2024, up 5.99% on a YoY basis from 0.13 in Q1 2024, and down 96.52% sequentially from 3.82 in Q3 2024.
Moolec Science (MLEC) Interest Coverage Ratio (2023 - 2024) Analysis & Trends
Moolec Science (MLEC) has 2 years of Interest Coverage Ratio data on file, last reported at 0.13 in Q4 2024.
- For the quarter ending Q4 2024, Interest Coverage Ratio rose 5.99% year-over-year to 0.13; the trailing twelve-month figure through Dec 2024 stood at 0.17 (down 74.26% YoY), and the FY2024 full-year result was 0.24, up 21.25% from the prior year.
- Interest Coverage Ratio retreated to 0.13 in Q4 2024, from 3.82 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 22.81 in Q3 2023 to a low of 0.13 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 7.60 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -0.22 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -0.38 |
| 10 | Moolec Science | 5.21 Bn | 5.21 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 0.13 |
| Sep 30, 2024 | 3.82 |
| Jun 30, 2024 | 0.08 |
| Mar 31, 2024 | 5.69 |
| Dec 31, 2023 | 0.13 |
| Sep 30, 2023 | 22.81 |
| Jun 30, 2023 | -0.13 |